Posts tagged BLUE


Polar Capital Steps Into Aurinia Pharmaceuticals Inc (AUPH), Kite Pharma Inc (KITE), But Gives bluebird bio Inc (BLUE) the Axe

A First Glance at This Hedge Fund Firm’s Strategic Q2 Moves in Biotech Sector

Read more

Thursday’s Market Insights: DryShips Inc. (DRYS), Himax Technologies, Inc. (ADR) (HIMX), bluebird bio Inc (BLUE)

Here’s a Running Tab of Updates Which We Find Most Relevant

Read more

Why These Biotech Stocks Tumbled Today: Ocular Therapeutix Inc (OCUL) and bluebird bio Inc (BLUE)

Ocular Therapeutix Inc Ocular Therapeutix Inc (NASDAQ:OCUL) investors seem to be concerned with the company’s future …

Read more

bluebird bio Inc (BLUE) Leads the Way in the Next Wave of CAR-Ts

Cowen analyst Eric Schmidt is out today with a research note on shares of bluebird bio Inc …

Read more

Company Update (NASDAQ:BLUE): bluebird bio Inc and apceth Biopharma Announces Commercial Drug Product Manufacturing Agreement

bluebird bio Inc (NASDAQ:BLUE) and apceth Biopharma announced today that they have entered into a …

Read more

Company Update (NASDAQ:BLUE): bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product in Phase 3 Trial of Patients with Transfusion-Dependent β-Thalassemia

bluebird bio Inc (NASDAQ: BLUE) announced treatment of the first patient in Northstar-2, the Phase …

Read more

Roth Capital Sees Room for Optimism Following bluebird bio Inc (BLUE) ASH Read-Out

During last week’s American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, …

Read more

Stock Update (NASDAQ:BLUE): Bluebird Bio Inc Announces Pricing of Public Offering of Common Stock

bluebird bio Inc (NASDAQ:BLUE) announced the pricing of an underwritten public offering of 3,289,473 shares …

Read more

Stock Update (NASDAQ:BLUE): Bluebird Bio Inc Announces Proposed Public Offering of Common Stock

bluebird bio Inc (NASDAQ:BLUE) announced that it has commenced an underwritten public offering of $200 …

Read more

Merrill Lynch Offer Commentary On Bluebird Bio Inc (BLUE) Following Phase 1 Results In Relapsed/Refractory Multiple Myeloma

bluebird bio Inc (NASDAQ:BLUE) just announced Phase 1 results of bb2121, the BCMA CAR-T therapy, …

Read more